Modern Vaccines Adjuvants & Delivery Systems

12-14 September 2017, Crowne Plaza Hotel, Porto, Portugal

  • Increase font size
  • Default font size
  • Decrease font size

Day Two

Final Conference Programme | Wednesday 13th September 2017

SESSION 5: Special Session
‘Precision Vaccines & Adjuvants’

Moderators: Ofer Levy
(Boston Children’s Hospital/Harvard Medical School, Boston, Massachusetts, USA)
Martin Bachmann
(Inselspital, Bern, Switzerland / University of Oxford, Oxford, UK)

Sponsored and organized in conjunction with Precision Vaccines Program, Boston Children’s Hospital/Harvard Medical School, Boston, Massachusetts, USA

‘High throughput screening, human in vitro modeling, and systems biology to inform development of novel age-specific adjuvanted vaccines’
Ofer Levy
(Boston Children’s Hospital/Harvard Medical School, Boston, Massachusetts, USA)

‘Discovery and development of Small Molecule Immune Potentiators (SMIPs)’
Derek O’Hagan
(GSK, Rockville, Maryland, USA)

‘An attempt to develop a universal technology for the development of precision cancer vaccines’
Martin Bachmann
(Inselspital, Bern, Switzerland / University of Oxford, Oxford, UK)

Coffee Break & Posters


Moderator: Martin Bachmann
(Inselspital, Bern, Switzerland / University of Oxford, Oxford, UK)

‘GM-CSF adjuvanted influenza vaccine delivery with dissolvable microneedle patches increases potency and breadth of immunity’
Ioanna Skountzou
(Emory University, Atlanta, Georgia, USA)

‘The use of new adjuvants and VLPs for the development of vaccines for emerging and infectious diseases’
Gustavo Cabral de Miranda
(University of Oxford, Oxford, UK)

‘Versatile nanoparticle platform for multifunctional vectorization and epitope delivery’
Pricillia Lagoutte, Adrien Lugari, Gustavo Stadthagen, Charlotte Mignon, Stephanie Donnat, Mourad Bekhouche, Natacha Mariano and Bettina Werle
(Bioaster, Lyon, France)

‘Evaluation of self-assembling protein nanoparticles (SAPN) for multi-antigen display’
Evelina Angov1, Elke S. Bergmann-Leitner1, Zoltan Beck2, Katherine L. Mallory1, Christopher Mann1, Neeraja Punde1, David E. Lanar1, Carl Alving2, Gary R. Matyas2 and Peter Burkhard3
(1 Military Malaria Research Program, Malaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring Maryland, USA; 2 Military HIV Research Program, Laboratory of Adjuvant and Antigen Research, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA; 3 Alpha-O Peptides AG, Riehen, Switzerland)

‘Adjuvants differentially influence germinal center kinetics’
Gabriel Pedersen, Peter Andersen and Dennis Christensen
(Statens Serum Institut, Copenhagen, Denmark)

Lunch Break & Posters


Moderator: Jeffrey A. Hubbell
(University of Chicago, Chicago, Illinois, USA)

‘Soluble glycopolymer conjugates as nanovaccines’
Jeffrey A. Hubbell
(University of Chicago, Chicago, Illinois, USA)

‘Afluria quadrivalent influenza vaccine: A challenging history overcome’
Heather Davis
(Seqirus, Maidenhead, Berkshire, UK)

‘MACIVIVA: Manufacturing of cold-chain independent virosome-based vaccine’
Mario Amacker, Sylvain Fleury and Toon Stegmann
(Mymetics SA, Epalinges, Switzerland)

‘Novel antigen-carrier system for multi-epitope subunit vaccine candidate against tuberculosis’
Kata Horvati1, Gergö Gyulai2, Éva Kiss2, Bernadett Pályi3, Zoltán Kis3, Sándor Dávid4, Nóra Szabó4, Kinga Fodor5 and Szilvia Bösze1
(1 MTA-ELTE Research Group of Peptide Chemistry, Budapest, Hungary; 2 Laboratory of Interfaces and Nanostructures, Eötvös L. University, Budapest, Hungary; 3 National Biosafety Laboratory, National Center for Epidemiology, Budapest, Hungary; 4 Laboratory of Bacteriology, Korányi National Institute for Tuberculosis, Budapest, Hungary; 5 Department of Veterinary Forensics, Law and Economics, University of Veterinary Medicine, Budapest, Hungary)

Tea Break & Posters


Moderator: Heather Davis
(Seqirus, Maidenhead, Berkshire, UK)

‘Vaccination in aging: Beyond the B lymphocyte lineage’
Doron Melamed
(Rappaport Faculty of Medicine, Technion/Israel Institute of Technology, Haifa, Israel)

‘First in human clinical trial of a novel, chemokine fusion DNA cancer vaccine’
Larry W. Kwak3, Soung-chul Cha1, D. Lynne Smith3, Sapna R. Parshottham2, Sheetal Rao2, Vincent Y. Lee1, Sattva S. Neelapu1 and Sheeba K. Thomas1
(1 Department of Lymphoma/Myeloma, Division of Cancer Medicine, and 2 Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; 3 Toni Stephenson Lymphoma Center, Department of Hematology and Hematopoietic Stem Cell Transplantation, Beckman Research Institute of City of Hope, Duarte, California, USA)

‘NLRC4-driven immunogenicity of a novel rMVA vaccine encoding flagellin and the induction of mucosal immune responses’
Stephanie L. Sanos, Ronny Kassub, Marco Testori, Raphael Giessel, Marlene Geiger, Johanna Knallinger, Juliane Pätzold, Barbara Bathke, Paul Chaplin, Hubertus Hochrein and Henning Lauterbach
(Bavarian Nordic GmbH, Martinsried, Germany)


MVADS 2017 Delegates

Login details will be supplied after you have registered for the event.

MVADS 2017 Sponsors

  • Mucosis
  • Sanofi Pasteur
  • Univac
  • Precision Vaccines Program
  • Brenntag
  • Matrivax
  • VisMederi
  • Pfizer
  • Vaxart
  • National Institute of Allergy and Infectious Diseases
  • EVI
  • IDRI
  • Bill and Melinda Gates Foundation
  • Novavax
  • Aldevron
  • Mymetics
  • CureVac
  • Janssen
  • iZon Science
  • Inovio
  • BIA Separations
  • BioAster
  • Seppic
  • BPRC
  • Eurocine Vaccines

MVADS 2017 Downloads

MVADS 2017 Leaflet

MVADS 2017 Mailing List

E-mail Address
What is 3+2-1?